The single-dose injection can help prevent RSV. Learn how it works and when your baby may be eligible.

Last fall, hospitals across the United States experienced a surge of children infected with respiratory syncytial virus, a common illness that can have serious effects on infants. They include an ...

Credit: Merck Enflonsia is an extended half-life RSV fusion glycoprotein neutralizing monoclonal antibody. The product is administered as a single intramuscular injection using the same dose ...

Globally, RSV causes millions of respiratory infections each year and is responsible for a large proportion of hospitalizations and deaths among children under five years, with the highest risk ...

Interim findings show clesrovimab has a similar safety profile to palivizumab. Clesrovimab, an investigational respiratory syncytial virus (RSV) fusion glycoprotein neutralizing monoclonal antibody, ...

Integrated Immunoprevention Strategies to Protect Infants from RSV. This schematic summarizes the position of the Mexican Association of Pediatrics on respiratory syncytial virus (RSV) ...

NEW YORK--(BUSINESS WIRE)--Pfizer Inc. (NYSE: PFE) announced today that the U.S. Food and Drug Administration (FDA) has approved ABRYSVO™ (Respiratory Syncytial Virus Vaccine), the company’s bivalent ...

The safety of the monoclonal antibody nirsevimab and the effect of nirsevimab on hospitalizations for respiratory syncytial virus (RSV)–associated lower respiratory tract infection when administered ...

During the first respiratory syncytial virus (RSV) season in France, passive infant immunisation with nirsevimab was associated with a lower risk for hospitalisation for RSV-related lower respiratory ...

Acceptance of respiratory syncytial virus (RSV) immunizations in the United States is growing, particularly for older adults, ...